Current progress in antiviral strategies

Trends in Pharmacological Sciences

Volumn 35, Issue 2, 2014, Pages 86-102

  Lou, Zhiyong ^a   Sun, Yuna ^b   Rao, Zihe ^a,b  

^a Tsinghua University   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

Author keywords

direct virus targeting antiviral; host targeting antiviral; indirect virus targeting antiviral

Indexed keywords

DIRECT VIRUS-TARGETING ANTIVIRAL; HOST-TARGETING ANTIVIRAL; INDIRECT VIRUS-TARGETING ANTIVIRAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; VIRUS DISEASES;

EID: 84895076942     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2013.11.006     Document Type: Review

References (145)

1. Y. Mao et al. Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer Proc. Natl. Acad. Sci. U.S.A. 110 2013 12438 12443
2. I.S. Georgiev et al. Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site Curr. Opin. HIV AIDS 8 2013 382 391
3. J.B. Lyczak, and S.L. Morrison Biological and pharmacokinetic properties of a novel immunoglobulin-CD4 fusion protein Arch. Virol. 139 1994 189 196
4. R.T. Schooley et al. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A Phase I-II escalating dosage trial Ann. Intern. Med. 112 1990 247 253
5. J.M. Jacobson et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542 Antimicrob. Agents Chemother. 48 2004 423 429
6. G.J. Hanna et al. Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects Antimicrob. Agents Chemother. 55 2012 722 728
7. B. Nowicka-Sans et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068 Antimicrob. Agents Chemother. 56 2012 3498 3507
8. K.A. Hooper, and J.D. Bloom A mutant influenza virus that uses an n1 neuraminidase as the receptor-binding protein J. Virol. 87 2013 12531 12540
9. P.M. Colman et al. Structure of the catalytic and antigenic sites in influenza virus neuraminidase Nature 303 1983 41 44
10. J.N. Varghese et al. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution Nature 303 1983 35 40
11. M.G. Ison Antivirals and resistance: influenza virus Curr. Opin. Virol. 1 2011 563 573
12. M. Yamashita Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza Antivir. Chem. Chemother. 21 2010 71 84
13. J.E. Hernandez et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States Clin. Infect. Dis. 52 2011 695 706
14. C. Chen et al. Crystal structure of enterovirus 71 RNA-dependent RNA polymerase complexed with its protein primer VPg: implication for a trans mechanism of VPg uridylylation J. Virol. 87 2013 5755 5768
15. Y. Sun et al. Enterovirus 71 VPg uridylation uses a two-molecular mechanism of 3D polymerase J. Virol. 86 2012 13662 13671
16. C. Porta et al. Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen PLoS Pathog. 9 2013 e1003255
17. E.E. Fry et al. Crystal structure of equine rhinitis A virus in complex with its sialic acid receptor J. Gen. Virol. 91 2010 1971 1977
18. S.D. Marlin et al. A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection Nature 344 1990 70 72
19. M.A. Murray, and L.M. Babe Inhibitory effect of dibenzofuran and dibenzosuberol derivatives on rhinovirus replication in vitro; effective prevention of viral entry by dibenzosuberenone Antiviral Res. 44 1999 123 131
20. C.T. Wild et al. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection Proc. Natl. Acad. Sci. U.S.A. 91 1994 9770 9774
21. J.M. Kilby et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry Nat. Med. 4 1998 1302 1307
22. J.M. Kilby et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults AIDS Res. Hum. Retroviruses 18 2002 685 693
23. J.P. Lalezari et al. A Phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy AIDS 17 2003 691 698
24. Y. He et al. Potent HIV fusion inhibitors against enfuvirtide-resistant HIV-1 strains Proc. Natl. Acad. Sci. U.S.A. 105 2008 16332 16337
25. Y. He Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion Curr. Pharm. Des. 19 2013 1800 1809
26. J.J. Dwyer et al. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus Proc. Natl. Acad. Sci. U.S.A. 104 2007 12772 12777
27. Y. He et al. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor J. Biol. Chem. 283 2008 11126 11134
28. F.M. Veronese, and G. Pasut PEGylation, successful approach to drug delivery Drug Discov. Today 10 2005 1451 1458
29. A.M. Sinclair, and S. Elliott Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins J. Pharm. Sci. 94 2005 1626 1635
30. H. Wang et al. ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation Antimicrob. Agents Chemother. 53 2009 4987 4998
31. S. Jiang et al. Design, synthesis, and biological activity of novel 5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl) thi azolidin-4-ones as HIV-1 fusion inhibitors targeting gp41 J. Med. Chem. 54 2011 572 579
32. A.R. Katritzky et al. Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2- thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors J. Med. Chem. 52 2009 7631 7639
33. E.J. Murray et al. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41 J. Virol. 84 2010 7288 7299
34. S.C. Harrison Viral membrane fusion Nat. Struct. Mol. Biol. 15 2008 690 698
35. J. Ren et al. Picornavirus uncoating intermediate captured in atomic detail Nat. Commun. 4 2013 1929
36. G. Zhang et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection Arch. Virol. 157 2011 669 679
37. H.A. Rotbart Treatment of picornavirus infections Antiviral Res. 53 2002 83 98
38. D.K. Phelps, and C.B. Post A novel basis of capsid stabilization by antiviral compounds J. Mol. Biol. 254 1995 544 551
39. S.K. Tsang et al. Stabilization of poliovirus by capsid-binding antiviral drugs is due to entropic effects J. Mol. Biol. 296 2000 335 340
40. K.S. Shia et al. Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors J. Med. Chem. 45 2002 1644 1655
41. D.F. Summers, and J.V. Maizel Jr Evidence for large precursor proteins in poliovirus synthesis Proc. Natl. Acad. Sci. U.S.A. 59 1968 966 971
42. H.R. Pelham Translation of encephalomyocarditis virus RNA in vitro yields an active proteolytic processing enzyme Eur. J. Biochem. 85 1978 457 462
43. V. Thiel et al. Mechanisms and enzymes involved in SARS coronavirus genome expression J. Gen. Virol. 84 2003 2305 2315
44. B.H. Harcourt et al. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity J. Virol. 78 2004 13600 13612
45. K. Ratia et al. Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme Proc. Natl. Acad. Sci. U.S.A. 103 2006 5717 5722
46. C. Schlieker et al. Structure of a herpesvirus-encoded cysteine protease reveals a unique class of deubiquitinating enzymes Mol. Cell 25 2007 677 687
47. M.Y. Balakirev et al. Deubiquitinating function of adenovirus proteinase J. Virol. 76 2002 6323 6331
48. Z. Sun et al. The cysteine protease domain of porcine reproductive and respiratory syndrome virus nonstructural protein 2 possesses deubiquitinating and interferon antagonism function J. Virol. 84 2010 7832 7846
49. J.M. Llibre et al. From TMC114 to darunavir: five years of data on efficacy AIDS Rev. 15 2013 112 121
50. M. Nijhuis et al. Implications of antiretroviral resistance on viral fitness Curr. Opin. Infect. Dis. 14 2001 23 28
51. B.L. Pearlman Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care Lancet Infect. Dis. 12 2012 717 728
52. N. Andany, and M.R. Loutfy HIV protease inhibitors in pregnancy: pharmacology and clinical use Drugs 73 2013 229 247
53. B. Oberg Rational design of polymerase inhibitors as antiviral drugs Antiviral Res. 71 2006 90 95
54. G. Andrei et al. Drug targets in cytomegalovirus infection Infect. Disord. Drug Targets 9 2009 201 222
55. A. Billich Entecavir (Bristol-Myers Squibb) Curr. Opin. Investig. Drugs 2 2001 617 621
56. E. Palumbo New drugs for chronic hepatitis B: a review Am. J. Ther. 15 2008 167 172
57. C.M. Wegzyn, and D.L. Wyles Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV) Curr. Opin. Pharmacol. 12 2012 556 561
58. T. Miyasaka et al. A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine J. Med. Chem. 32 1989 2507 2509
59. H. Tanaka et al. A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) J. Med. Chem. 34 1991 349 357
60. M.E. Goldman et al. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity Proc. Natl. Acad. Sci. U.S.A. 88 1991 6863 6867
61. R.K. Rawal et al. Structure-activity relationship studies on clinically relevant HIV-1 NNRTIs Curr. Med. Chem. 19 2012 5364 5380
62. P.L. Beaulieu Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections Curr. Opin. Investig. Drugs 8 2007 614 634
63. S.L. Karmon, and M. Markowitz Next-generation integrase inhibitors: where to after raltegravir? Drugs 73 2013 213 228
64. P. Messiaen et al. Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis PLoS ONE 8 2013 e52562
65. P.E. Sax et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks Lancet 379 2012 2439 2448
66. C.G. Noble, and P.Y. Shi Structural biology of dengue virus enzymes: towards rational design of therapeutics Antiviral Res. 96 2013 115 126
67. D. Benarroch et al. A structural basis for the inhibition of the NS5 dengue virus mRNA 2′-O-methyltransferase domain by ribavirin 5′-triphosphate J. Biol. Chem. 279 2004 35638 35643
68. M. Milani et al. Flaviviral methyltransferase/RNA interaction: structural basis for enzyme inhibition Antiviral Res. 83 2009 28 34
69. H. Dong et al. Structural and functional analyses of a conserved hydrophobic pocket of flavivirus methyltransferase J. Biol. Chem. 285 2010 32586 32595
70. H.J. Stahla-Beek et al. Identification of a novel antiviral inhibitor of the flavivirus guanylyltransferase enzyme J. Virol. 86 2012 8730 8739
71. Y.S. Keum, and Y.J. Jeong Development of chemical inhibitors of the SARS coronavirus: viral helicase as a potential target Biochem. Pharmacol. 84 2012 1351 1358
72. S.P. Seguin et al. A screen for modulators of large T antigen's ATPase activity uncovers novel inhibitors of Simian Virus 40 and BK virus replication Antiviral Res. 96 2012 70 81
73. P.W. White et al. Biphenylsulfonacetic acid inhibitors of the human papillomavirus type 6 E1 helicase inhibit ATP hydrolysis by an allosteric mechanism involving tyrosine 486 Antimicrob. Agents Chemother. 49 2005 4834 4842
74. W.R. Shadrick et al. Discovering new medicines targeting helicases: challenges and recent progress J. Biomol. Screen. 18 2012 761 781
75. A.M. Faucher et al. Discovery of small-molecule inhibitors of the ATPase activity of human papillomavirus E1 helicase J. Med. Chem. 47 2004 18 21
76. C.S. Chen et al. Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase J. Med. Chem. 52 2009 2716 2723
77. Y. Chen et al. Characterization of aurintricarboxylic acid as a potent hepatitis C virus replicase inhibitor Antivir. Chem. Chemother. 20 2009 19 36
78. C.A. Belon, and D.N. Frick NS3 helicase inhibitors Y. He, S.L. Tan, Hepatitis C: Antiviral Drug Discovery and Development 2011 Caister Academic 237 256
79. A.D. Kwong et al. Viral and cellular RNA helicases as antiviral targets Nat. Rev. Drug Discov. 4 2005 845 853
80. P.D. Nagy, and J. Pogany The dependence of viral RNA replication on co-opted host factors Nat. Rev. Microbiol. 10 2012 137 149
81. M. Gao et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
82. V. Ambros, and D. Baltimore Protein is linked to the 5′ end of poliovirus RNA by a phosphodiester linkage to tyrosine J. Biol. Chem. 253 1978 5263 5266
83. C. Ferrer-Orta et al. The structure of a protein primer-polymerase complex in the initiation of genome replication EMBO J. 25 2006 880 888
84. A. Gruez et al. The crystal structure of coxsackievirus B3 RNA-dependent RNA polymerase in complex with its protein primer VPg confirms the existence of a second VPg binding site on Picornaviridae polymerases J. Virol. 82 2008 9577 9590
85. P. Kranzusch, and S. Whelan Architecture and regulation of negative-strand viral enzymatic machinery RNA Biol. 9 2012 941 948
86. A. Ariza et al. Nucleocapsid protein structures from orthobunyaviruses reveal insight into ribonucleoprotein architecture and RNA polymerization Nucleic Acids Res. 41 2013 5912 5926
87. R. Arranz et al. The structure of native influenza virion ribonucleoproteins Science 338 2013 1634 1637
88. Y. Guo et al. Crimean-Congo hemorrhagic fever virus nucleoprotein reveals endonuclease activity in bunyaviruses Proc. Natl. Acad. Sci. U.S.A. 109 2012 5046 5051
89. K.M. Hastie et al. Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3′ to 5′ exonuclease activity essential for immune suppression Proc. Natl. Acad. Sci. U.S.A. 108 2011 2396 2401
90. K.M. Hastie et al. Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding Proc. Natl. Acad. Sci. U.S.A. 108 2011 19365 19370
91. B. Li et al. Bunyamwera virus possesses a distinct nucleocapsid protein to facilitate genome encapsidation Proc. Natl. Acad. Sci. U.S.A. 110 2013 9048 9053
92. A. Moeller et al. Organization of the influenza virus replication machinery Science 338 2013 1631 1634
93. X. Qi et al. Cap binding and immune evasion revealed by Lassa nucleoprotein structure Nature 468 2011 779 783
94. D.D. Raymond et al. Phleboviruses encapsidate their genomes by sequestering RNA bases Proc. Natl. Acad. Sci. U.S.A. 109 2012 19208 19213
95. D.D. Raymond et al. Structure of the Rift Valley fever virus nucleocapsid protein reveals another architecture for RNA encapsidation Proc. Natl. Acad. Sci. U.S.A. 107 2010 11769 11774
96. J. Reguera et al. Structural basis for encapsidation of genomic RNA by La Crosse Orthobunyavirus nucleoprotein Proc. Natl. Acad. Sci. U.S.A. 110 2013 7246 7251
97. R.Y. Kao et al. Identification of influenza A nucleoprotein as an antiviral target Nat. Biotechnol. 28 2010 600 605
98. S.W. Gerritz et al. Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers Proc. Natl. Acad. Sci. U.S.A. 108 2011 15366 15371
99. X. He et al. Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza H5N1 virus Nature 454 2008 1123 1126
100. K. Wunderlich et al. Identification of high-affinity PB1-derived peptides with enhanced affinity to the PA protein of influenza A virus polymerase Antimicrob. Agents Chemother. 55 2011 696 702
101. K. Wunderlich et al. Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication PLoS ONE 4 2009 e7517
102. B. Manz et al. Disruption of the viral polymerase complex assembly as a novel approach to attenuate influenza A virus J. Biol. Chem. 286 2011 8414 8424
103. H. Zhou et al. The nucleoprotein of severe fever with thrombocytopenia syndrome virus processes a stable hexameric ring to facilitate RNA encapsidation Protein Cell 4 2013 445 455
104. Y. Wang et al. Structure of Crimean-Congo haemorraghic fever virus nucleoprotein: superhelical homo-oligomers and the role of caspase-3 cleavage J. Virol. 86 2012 12294 12303
105. N. Goudreau et al. Optimization and determination of the absolute configuration of a series of potent inhibitors of human papillomavirus type-11 E1-E2 protein-protein interaction: a combined medicinal chemistry, NMR and computational chemistry approach Bioorg. Med. Chem. 15 2007 2690 2700
106. C. Thomas et al. Structural linkage between ligand discrimination and receptor activation by type I interferons Cell 146 2012 621 632
107. N. Yan, and Z.J. Chen Intrinsic antiviral immunity Nat. Immunol. 13 2012 214 222
108. D.M. Hotho et al. Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: early effects of active substance use Antiviral Res. 97 2013 347 355
109. L.J. Scott, and C.M. Perry Interferon-α-2b plus ribavirin: a review of its use in the management of chronic hepatitis C Drugs 62 2002 507 556
110. M. Enomoto et al. Dynamics of hepatitis C virus monitored by real-time quantitative polymerase chain reaction during first 2 weeks of IFN-β treatment are predictive of long-term therapeutic response J. Interferon Cytokine Res. 22 2002 389 395
111. R. Kumashiro et al. Interferon-γ brings additive anti-viral environment when combined with interferon-α in patients with chronic hepatitis C Hepatol. Res. 22 2002 20 26
112. F. Negro et al. Treatment of chronic hepatitis C with α-interferon plus ofloxacin in patients not responding to α-interferon alone J. Hepatol. 29 1998 369 374
113. M. Tsutsumi et al. Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: a pilot study J. Gastroenterol. Hepatol. 11 1996 1006 1011
114. S. Moscarella et al. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results Liver 18 1998 366 369
115. A. Kozlowski et al. Development of pegylated interferons for the treatment of chronic hepatitis C BioDrugs 15 2001 419 429
116. R.E. Handschumacher et al. Cyclophilin: a specific cytosolic binding protein for cyclosporin A Science 226 1984 544 547
117. X. Liu et al. Insights into the roles of cyclophilin A during influenza virus infection Viruses 5 2013 182 191
118. J. Liu et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes Cell 66 1991 807 815
119. M. Bienkowska-Haba et al. Target cell cyclophilins facilitate human papillomavirus type 16 infection PLoS Pathog. 5 2009 e1000524
120. X. Tian et al. Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin A secretion: possible link to pathogenesis of HBV infection J. Virol. 84 2010 3373 3381
121. S. Bose et al. Requirement for cyclophilin A for the replication of vesicular stomatitis virus New Jersey serotype J. Gen. Virol. 84 2003 1687 1699
122. C. Luo et al. Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A Biochem. Biophys. Res. Commun. 321 2004 557 565
123. H. He et al. Cyclophilin A inhibits rotavirus replication by facilitating host IFN-I production Biochem. Biophys. Res. Commun. 422 2012 664 669
124. J. Colgan et al. Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization J. Virol. 70 1996 4299 4310
125. K. Zander et al. Cyclophilin A interacts with HIV-1 Vpr and is required for its functional expression J. Biol. Chem. 278 2003 43202 43213
126. K. Bruns et al. Structural characterization of the HIV-1 Vpr N terminus: evidence of cis/trans-proline isomerism J. Biol. Chem. 278 2003 43188 43201
127. S.M. Solbak et al. HIV-1 p6-Another viral interaction partner to the host cellular protein cyclophilin A Biochim. Biophys. Acta 1824 2012 667 678
128. S.M. Solbak et al. The host-pathogen interaction of human cyclophilin A and HIV-1 Vpr requires specific N-terminal and novel C-terminal domains BMC Struct. Biol. 11 2011 49
129. K. Watashi et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes Hepatology 38 2003 1282 1288
130. Z. Liu et al. Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex J. Virol. 83 2009 6554 6565
131. T.L. Tellinghuisen et al. Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein J. Virol. 82 2008 1073 1083
132. M.A. Wainberg et al. The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1 Blood 72 1988 1904 1910
133. L. Coelmont et al. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitor Antimicrob. Agents Chemother. 53 2009 967 976
134. S. Hopkins et al. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro Antimicrob. Agents Chemother. 54 2010 660 672
135. R.G. Ptak et al. Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent Antimicrob. Agents Chemother. 52 2008 1302 1317
136. J. Lalezari et al. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults AIDS 19 2005 1443 1448
137. D.A. Cooper et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection J. Infect. Dis. 201 2010 803 813
138. M.M. Caseiro et al. Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials J. Infect. 65 2012 326 335
139. J.F. Marier et al. Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naive patients Antimicrob. Agents Chemother. 55 2011 2768 2774
140. J. Lalezari et al. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects J. Acquir. Immune Defic. Syndr. 57 2011 118 125
141. Q. Tan et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex Science 341 2013 1387 1390
142. B. Wu et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists Science 330 2010 1066 1071
143. P. Ahlquist Parallels among positive-strand RNA viruses, reverse-transcribing viruses and double-stranded RNA viruses Nat. Rev. Microbiol. 4 2006 371 382
144. C.C. Huang et al. Structure of a V3-containing HIV-1 gp120 core Science 310 2005 1025 1028
145. X. Wang et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71 Nat. Struct. Mol. Biol. 19 2011 424 429